title: Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women.
abstract: BACKGROUND
  Isoflavones from soybeans may provide some beneficial impacts on postmenopausal health. The purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai women.
  
  
  METHODS
  We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai women. In the first phase, each subject randomly received either 2 soy extract capsules (containing daidzin : genistin = 7.79 : 22.57 mg), or soy beverage prepared from 15 g of soy flour (containing daidzin : genistin = 9.27 : 10.51 mg). In the second phase, the subjects received an alternative preparation in the same manner after a washout period of at least 1 week. Blood samples were collected immediately before and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 h after administration of the soy preparation in each phase. Plasma daidzein and genistein concentrations were determined by using high performance liquid chromatography (HPLC). The pharmacokinetic parameters of daidzein and genistein, i.e. maximal plasma concentration (Cmax), time to maximal plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (t1/2), were estimated using the TopFit version 2.0 software with noncompartmental model analysis.
  
  
  RESULTS
  There were no significant differences in the mean values of Cmax/dose, AUC0-32/dose, AUC0- proportional, variant/dose, Tmax, and t1/2 of genistein between both preparations. For pharmacokinetic parameters of daidzein, the mean values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations. Nonetheless, the mean AUC0-32/dose and AUC0- proportional, variant/dose after administration of soy extract capsules were slightly (but significantly, p < 0.05) higher than those of soy beverage.
  
  
  CONCLUSIONS
  The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules, whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were comparable. The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the dose, Tmax and t1/2, were not different between both soy preparations.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Thailand. ekasin_min@hotmail.com <ekasin_min@hotmail.com>
authors.forename: Ekasin
authors.initials: E
authors.lastname: Anupongsanugool
authors.forename: Supanimit
authors.initials: S
authors.lastname: Teekachunhatean
authors.forename: Noppamas
authors.initials: N
authors.lastname: Rojanasthien
authors.forename: Saipin
authors.initials: S
authors.lastname: Pongsatha
authors.forename: Chaichan
authors.initials: C
authors.lastname: Sangdee
mesh_terms: D002214:Capsules; D018592:Cross-Over Studies; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D017698:Postmenopause / Q000097:blood* / Q000187:drug effects; D041942:Soy Milk / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013785:Thailand
chemical_list: D002214:Capsules; D007529:Isoflavones; D010936:Plant Extracts; C004742:daidzein; D019833:Genistein
references.citation: Am J Epidemiol. 1997 Sep 15;146(6):502-9
references.pmid: 9290511
references.citation: J Nutr. 1996 Apr;126(4):871-7
references.pmid: 8613890
references.citation: Endocrinology. 1998 Oct;139(10):4252-63
references.pmid: 9751507
references.citation: J Nutr. 1998 Oct;128(10):1710-5
references.pmid: 9772140
references.citation: Am J Clin Nutr. 1998 Dec;68(6 Suppl):1474S-1479S
references.pmid: 9848519
references.citation: Biochem Soc Trans. 1999 Feb;27(2):304-8
references.pmid: 10093753
references.citation: J Nutr. 2000 Apr;130(4):798-801
references.pmid: 10736332
references.citation: J AOAC Int. 2000 May-Jun;83(3):635-50
references.pmid: 10868587
references.citation: Menopause. 2000 Jul-Aug;7(4):236-42
references.pmid: 10914616
references.citation: Expert Opin Investig Drugs. 2000 Aug;9(8):1829-40
references.pmid: 11060780
references.citation: Drug Metabol Drug Interact. 2000;17(1-4):261-89
references.pmid: 11201299
references.citation: J Nutr. 2001 Apr;131(4 Suppl):1362S-75S
references.pmid: 11285356
references.citation: J Clin Endocrinol Metab. 2001 Jul;86(7):3053-60
references.pmid: 11443167
references.citation: Baillieres Clin Endocrinol Metab. 1998 Dec;12(4):605-23
references.pmid: 10384816
references.citation: J Chromatogr B Biomed Sci Appl. 2001 Sep 5;760(2):191-205
references.pmid: 11530977
references.citation: J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-362S; discussion 381S-383S
references.pmid: 11603644
references.citation: J Am Coll Nutr. 2002 Apr;21(2):97-102
references.pmid: 11999549
references.citation: Best Pract Res Clin Obstet Gynaecol. 2002 Jun;16(3):411-48
references.pmid: 12099671
references.citation: J Am Coll Nutr. 2002 Dec;21(6):560-3
references.pmid: 12480802
references.citation: Am J Med. 2002 Dec 30;113 Suppl 9B:71S-88S
references.pmid: 12566142
references.citation: Br J Nutr. 2004 Apr;91(4):567-74
references.pmid: 15035683
references.citation: JAMA. 2004 Apr 14;291(14):1701-12
references.pmid: 15082697
references.citation: Am J Obstet Gynecol. 2004 Apr;190(4):1141-67
references.pmid: 15118656
references.citation: N Engl J Med. 1995 Aug 3;333(5):276-82
references.pmid: 7596371
references.citation: Obstet Gynecol. 1998 Jan;91(1):6-11
references.pmid: 9464712